Johnson & Johnson: Heart Failure trials

The registry lists 42 Heart Failure studies with Johnson & Johnson as lead sponsor. 3 are open to participants now and 10 have results posted.

Phase 1 3Phase 2 10Phase 3 12Phase 4 1No phase 18(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EFNot yet recruitingNCT07696975Not applicable
• INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac RecoveryRecruitingNCT06965504Not applicable
• Impella Pump Return Study to Analyze Deposits and Biomaterial in Used PumpsRecruitingNCT06765226
• A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart FailureCompletedNCT04252287Phase 3Results posted
• A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular DiseaseCompletedNCT03153111Phase 2Results posted
• A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge PatientsCompletedNCT02111564Phase 3Results posted
• A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart FailureCompletedNCT01877915Phase 3Results posted
• Pilot Study of COR-1 in Heart FailureCompletedNCT01391507Phase 2Results posted
• A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart FailureCompletedNCT01120210Phase 2Results posted
• Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody CyclopeptideCompletedNCT01043146Phase 1Results posted
• An Exploratory Study of Nesiritide in Participants With Acute Heart FailureCompletedNCT00490724Phase 2Results posted
• A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart FailureCompletedNCT00475852Phase 3Results posted
• Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMACTerminatedNCT00338455Phase 2Results posted
• V-A ECMO AUTO Mode RegistryCompletedNCT05759377
• Breethe Abiomed Recovery RegisTry (BART)CompletedNCT05473130
• Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility StudyActive, not recruitingNCT05291884Not applicable
• SVC Occlusion in Subjects With Acute Decompensated Heart FailureCompletedNCT03836079Not applicable
• VITROS Immunodiagnostic Products NT-proBNP IICompletedNCT03548909
• Reducing Lung CongestIon Symptoms in Advanced Heart FailureActive, not recruitingNCT03499236Not applicable
• Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart FailureCompletedNCT03387215Phase 1/2
• Protected PCI StudyStatus unknownNCT02831881
• Heart Failure (HF) Interatrial Shunt Study 1WithdrawnNCT02511912Not applicable
• The V-Wave Shunt: FIM Safety and Feasibility StudyCompletedNCT01965015Not applicable
• A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor AutoantibodiesWithdrawnNCT01798745Phase 2
• The Use of Impella RP Support System in Patients With Right Heart FailureStatus unknownNCT01777607Not applicable
• Symphony: The Implantable Counter Pulsation Device (CPD) Safety and Feasibility TrialStatus unknownNCT01543022Phase 1/2
• Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure PatientsTerminatedNCT01185691Not applicable
• An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart FailureCompletedNCT00813202Phase 3
• Clinical Study to Evaluate Nesiritide in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery A014 / NAPACompletedNCT00653042Phase 2
• Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSSCompletedNCT00652652Phase 4
• Heart Failure RegistryCompletedNCT00530426
• An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)WithdrawnNCT00530361Phase 3
• Registry for Acute Decompensated Heart Failure PatientsCompletedNCT00366639
• Longitudinal Registry for Advanced Heart Failure PatientsCompletedNCT00364416
• Registry for Acute Decompensated Heart Failure Patients Admitted to the ERCompletedNCT00364325
• A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at RestCompletedNCT00288730Phase 3
• A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and Caliber of Blood VesselsCompletedNCT00271557Phase 3
• A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart FailureCompletedNCT00270400Phase 3
• A Study of Short-Term Outcomes and Economic Impact For Patients With Worsening Congestive Heart Failure When Natrecor (Nesiritide) is Added to Standard-Care Therapy, Compared to Administration of Placebo With Standard-Care TherapyCompletedNCT00270387Phase 3
• A Study Comparing Blood Flow and Clinical and Safety Effects of the Addition of Natrecor (Nesiritide), Placebo or Intravenous Nitroglycerin to Standard Care for the Treatment of Worsening Congestive Heart Failure.CompletedNCT00270374Phase 3
• FUSION I Assesses Safety and Tolerability of Two Doses of NATRECOR (Nesiritide) Administered to Patients With Worsening Congestive (Decompensated) Heart Failure Who Are Concurrently Receiving Their Usual Cardiac Medications and Are at High Risk for Hospitalization.CompletedNCT00270361Phase 3
• A Study of the Safety and Efficacy of Follow-up Serial Infusions of Natrecor(Nesiritide) for the Management of Patients With Heart FailureCompletedNCT00091520Phase 2